The agreement that is underway also includes reduced discounts that drug manufacturers are forced to accept in a system applied by the British NHS medicines authority.
According to the news agency, the settlement will be presented on Monday evening.
Britain – where, among other things, Swedish-British Astra Zeneca is located – has, according to Bloomberg's anonymous sources, agreed to set a cap on discounts of 15 percent, down from the current cap of 23 percent.
A trade barrier in the form of a threshold for what is considered a cost-effective medicine will simultaneously be lifted by around 25 percent.
